[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100625716":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":36,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":57,"whyStopped":7,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Aarhus University Hospital","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Louise B Callesen, MD, PhD","CONTACT","30482884","Louicall@rm.dk",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Karen-Lise G Spindler, Professor, MD, PhD","91167244","K.g.spindler@oncology.au.dk",[19],{"facility":20,"status":7,"city":21,"state":7,"zip":22,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"Department of Oncology, Aarhus University Hospital","Aarhus N","8200","Denmark","DK",{"type":26,"coordinates":27},"Point",[28,29],10.17317,56.20367,{"lat":29,"lon":28},[32,33,35],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"name":10,"role":34,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":15,"role":34,"phone":7,"phoneExt":7,"email":7},{"type":34,"investigatorFullName":37,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Louise Bach Callesen","Principal Investigator","100625716","clinical-utility-of-ctdna-in-the-treatment-of-oligometastatic-disease-100625716",false,"NCT07426250","Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease","Clinical Utility of ctDNA in the Treatment of Oligometastatic Disease - A Prospective Observational Clinical Study - A Part of the POB-project","Inclusion Criteria:\n\n* Metastatic spread from histopathological diagnosed solid cancer\n* Planned for LAT (local ablative therapy) for OMD (oligometastatic disease)\n* ≥ 18 years\n* Written and oral consent\n\nExclusion Criteria:\n\n* Other cancer disease within 5 years\n* Conditions that will contraindicate blood samples","ALL","18 Years",{"count":49,"type":50},500,"ESTIMATED","OBSERVATIONAL","This prospective observational study investigates the clinical utility of circulating tumor DNA (ctDNA) in patients with oligometastatic disease (OMD) undergoing definitive-intent local ablative treatment (LAT). The study aims to evaluate ctDNA as a prognostic and response biomarker before, during, and after LAT across cancer types and treatment modalities. Serial plasma samples and archival tumor tissue will be analyzed to assess ctDNA detection rates, elimination patterns, minimal residual disease, and association with recurrence, progression, and survival outcomes.",[54],"Oligometastatic Cancer",[56],"Local Ablative Treatment of Oligometastatic Disease","NOT_YET_RECRUITING","2026-02-16",{"date":60,"type":61},"2026-02-23","ACTUAL",{"date":63,"type":50},"2026-03-01",{"date":65,"type":50},"2030-09-01",{"name":5,"class":6},1]